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Interferon regulatory factor 5 (IRF-5) plays an important role in the innate antiviral and inflammatory
response. Specific IRF-5 haplotypes are associated with dysregulated expression of type I interferons and
predisposition to autoimmune disorders. IRF-5 is activated by Toll-like receptor 7 (TLR7) and TLR9 via the
MyD88 pathway, where it interacts with both MyD88 and the E3 ubiquitin ligase, TRAF6. To understand the
role of these interactions in the regulation of IRF-5, we examined the role of ubiquitination and showed that
IRF-5 is subjected to TRAF6-mediated K63-linked ubiquitination, which is important for IRF-5 nuclear
translocation and target gene regulation. We show that while the murine IRF-5 and human IRF-5 variant 4
(HuIRF-5v4) and HuIRF-5v5 are ubiquitinated, an IRF-5 bone marrow variant mutant containing an internal
deletion of 288 nucleotides is not ubiquitinated. Lysine residues at positions 410 and 411 in a putative TRAF6
consensus binding domain of IRF-5 are the targets of K63-linked ubiquitination. Mutagenesis of these two
lysines abolished IRF-5 ubiquitination, nuclear translocation, and the IFNA promoter-inducing activity but not
the IRF-5–TRAF6 interaction. Finally, we show that IRAK1 associates with IRF-5 and that this interaction
precedes and is required for IRF-5 ubiquitination and activation. Thus, our findings offer a new mechanistic
insight into IRF-5 gene induction program through hitherto unknown processes of IRF-5 ubiquitination.
Antiviral cytokines and chemokines are activated as an early
response to viral infection and play a critical role in both the
outcome of the infection and its pathogenicity. Dysregulation
of this response can have pathogenic consequences leading to
autoimmune diseases.
Two classes of cellular receptors recognize intracellular viral
nucleic acids. Toll-like receptors (TLRs), present in the endo-
somal compartments of immune cells, detect both viral RNA
and DNA(3), whereas TLR3 detects double-stranded RNA, a
common replication intermediate of both DNA and RNA vi-
ruses (4, 26). TLR7 and TLR8 detect single-stranded viral
genomic RNA (10), and DNA viruses are recognized by TLR9,
which detects the unmethylated CpG regions of viral genomic
DNA (21). TLR7 and TLR9 are expressed predominantly in
plasmacytoid dendritic cells, while conventional dendritic cells,
fibroblasts, and endothelial cells express TLR3. A second class
of receptors which also detects double-stranded RNA pro-
duced in infected cells is comprised of the ubiquitously ex-
pressed cytoplasmic RNA helicases including RIG-I and
MDA5 (33). These receptors signal via the caspase activation
and recruitment domains. Although recognition of viral nu-
cleic acids is mediated by distinct cellular receptors, which
mediate distinct signaling pathways, they all activate latent
transcription factors of the NF-B and interferon (IFN) regu-
latory factor (IRF) families (3, 15). While the inducible acti-
vation of inflammatory cytokines is largely dependent on NF-
B, IRF-3 and IRF-7 play a critical role in the induction of
type I IFN genes.
IRF-5 is a related family member that is implicated in the
innate inflammatory response, where it has been shown to
control induction not only of type I IFN genes but also of
inflammatory cytokines and chemokines. IRF-5 controls the
transcription of type I IFN genes in certain cell types, while its
role in the induction of inflammatory cytokines and chemo-
kines is more general (5, 7, 23). Several distinctly spliced hu-
man IRF-5 (HuIRF-5) isoforms (designated variants 1 to 10),
which show cell-type-specific expression and distinct cellular
localization, have recently been identified (9, 20, 22). The most
common variations feature insertions or deletions in exon 6. A
common single nucleotide polymorphism haplotype in IRF-5
was identified as a risk factor for systemic lupus erythematosus
(SLE) (12, 13), an autoimmune disease characterized by the
presence of excess type I IFN in the serum. Thus, the dysregu-
lated expression of type I IFNs, which is associated with SLE,
may be related to the presence of elevated levels of SLE-
promoting IRF-5 haplotypes.
Activation of IRF-5 is restricted to TLRs that signal via
MyD88, including TLR4, TLR5, TLR7, TLR8, and TLR9 (25).
MyD88-dependent activation of IRF-5 involves formation of a
tertiary complex consisting of interleukin-1-associated kinase 1
(IRAK1), IRAK4, tumor necrosis factor receptor-associated
factor 6 (TRAF6) together with IRF-5 or IRF-7 (18, 28).
Mechanistically, MyD88 is recruited to the TLRs upon ligand
binding, leading to the activation of IRAK1 and IRAK4, which
then associate with TRAF6. TRAF6 is a K63-specific ubiquitin
ligase that forms complexes exclusively with the UBC13 and
Uev1a/Mms2 heterodimer acting as an E2, which then pro-
motes synthesis of lysine 63-linked polyubiquitin chains (31).
Polyubiquitination through K63 does not generally target pro-
teins for proteasomal degradation but regulates important cel-
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lular process such as DNA repair (30) and signal transduction
(1). It was shown recently that in both TLR and nucleotide
oligomerization domain signaling pathways, TRAF6 mediates
K63-linked ubiquitination of NEMO (1) and increases activa-
tion of NF-B. Furthermore, it has been shown that, in re-
sponse to TLR9 ligands, TRAF6 binds to and ubiquitinates
IRF-7 and that the E3 ligase activity of TRAF6 is required
for IRF-7 ubiquitination. However, neither the functional role
of IRF-7 ubiquitination nor its mechanism was established
(18).
The aim of this study was to examine the molecular mech-
anism of IRF-5 activation by the MyD88-dependent TLR path-
way, focusing on the role of TRAF6-dependent K63-linked
ubiquitination of IRF-5 activation. We demonstrate that in
MyD88 signaling, IRF-5 associates with MyD88 and undergoes
K63-linked ubiquitination, translocation to the nucleus, and
association with the promoters of type I IFN genes. K63 ubiq-
uitination via TRAF6 targets lysines at positions 410 and 411,
which are located in the TRAF6 binding motif of IRF-5. The
mutations of lysine to arginine residues at these sites leads to
an accumulation of IRF-5 in the cytoplasm, resulting in abro-
gation of IRF-5-mediated stimulation of the IFNA promoter.
Finally, we show that IRF-5 interacts with IRAK1 and that
TRAF6 ubiquitination of IRF-5 is dependent on IRAK1 since
this was not detected in MyD88-stimulated IRAK1/ cells.
These results show that association of MyD88 with IRAK1
activates IRF-5 and that these events precede the TRAF6-
dependent ubiquitination of IRF-5, a critical event in the reg-
ulation of IRF-5 function.
MATERIALS AND METHODS
Expression plasmids. pcDNA6 Myc/His-tagged IRF-5 was described previ-
ously (23); hemagglutinin (HA)-tagged wild-type ubiquitin was a generous gift
from H. Gottlinger (University of Massachussetts Medical School, Worcester,
MA), and HA-tagged K63R and HA-tagged K48R were generously provided by
Z. Chen (University of Texas Southwestern Medical Center, Dallas, TX). The
IRF-5 K410R K411R (K410/K411R) point mutant was generated from pcDNA6-
IRF-5 through a QuikChange site-directed mutagenesis kit (Stratagene).
The IRF-5 variant 4 (IRF-5v4) C-terminal deletions were described previously
(6). The IRF-5v5 mutants containing C-terminal deletions after the TRAF6
consensus binding site PREKKL was generated by PCR. The amplification step
was performed with Pfu Turbo DNA polymerase (Stratagene). The BamHI and
EcoRI restriction sites were included in the primer design. The amplified frag-
ments were gel purified and cloned in-frame within the BamHI and EcoRI
restriction sites in the pCMV-3Tag vector-1 (catalogue no. 240195; Stratagene).
The sequence was confirmed by sequencing. The MyD88, TRAF6, IRAK1, and
IRAK1 D340N expression plasmids were described previously (11). Luciferase
reporter plasmids containing promoters of murine IFNA and IFNB genes were
a generous gift from T. Michiels (University of Louvain, Belgium).
Cell lines and antibodies. 293T cells were maintained in Dulbecco’s modified
Eagle’s medium with 5% fetal bovine serum (FBS). TRAF6/ mouse embry-
onic fibroblasts (MEFs) were kindly provided by Tak Mak (University of To-
ronto, Toronto, Canada) and 293TI1A IRAK1-deficient cells were a kind gift
from X. Li (Cleveland Clinic, Cleveland, OH) and were maintained in Dulbec-
co’s modified Eagle’s medium supplemented with 10% FBS and 2 mM glu-
tamine. RAW264.7 cells were cultured in RPMI medium supplemented with
10% FBS and stimulated with 100 ng/ml R848 for 8 h.
Polyclonal antibodies, rabbit MyD88, -actin, -tubulin, Sp-1 antibodies, and
monoclonal IRF-5 antibodies were purchased from Santa Cruz Biotechnology;
anti-HA antibody was purchased from (Roche), and antiubiquitin polyclonal
antibodies were purchased from Sigma. Mouse anti-His antibodies were from
Zymed Laboratories. Anti-mouse IRF-5 antibodies were generated in rabbits
against the VRFPSPEDIPSDKWR peptide by Affinity BioReagents. These an-
tibodies cross-react with HuIRF-5. The M2 anti-Flag beads were purchased from
Sigma. Antiubiquitin-Sepharose beads were purchased from Pierce Biotech.
Subcellular localization and chromatin immunoprecipitation (ChIP). For
preparation of the cytoplasmic extracts, cells were lysed in a buffer containing 20
mM Tris (pH 8), 10 mM NaCl, 3 mM MgCl2, 20% glycerol, 0.2 mM EDTA, 1
mM dithiothreitol (DTT), and 0.1% NP-40. Nuclear extracts were prepared from
2  107 293T cells that were lysed in a buffer containing 20 mM Tris (pH 8), 400
mM NaCl, 20% glycerol, 0.2 mM EDTA, 1 mM DTT, and protease and phos-
phatase inhibitor cocktail (Sigma).
For the ChIP analysis, 293T cells (2  107) were cotransfected with IRF-5 and
a combination of MyD88, TRAF6, and ubiquitin-expressing plasmids (1 g of
each). At 24 h posttransfection the ChIP assay was done as described previously
(6). Briefly, proteins bound to DNA were cross-linked by the addition of form-
aldehyde to a final concentration of 1% for 30 min at 37°C, and the cross-linking
was stopped by the addition of glycine to a final concentration of 0.125 M. Cells
were then washed twice in ice-cold phosphate-buffered saline containing 1 mM
phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, and 1 g/ml pepstatin; cells
were pelleted, resuspended in 200 l of sodium dodecyl sulfate (SDS) lysis
buffer, and sonicated for 1 min. Samples were precleared with protein A-agarose
beads, and the input DNA levels were measured in 1% of the total precleared
sample. Samples were then immunoprecipitated with polyclonal anti-IRF-5 (2
g) or immunoglobulin G antibody (Affinity BioReagents). Immune complexes
were washed and resuspended in Tris-EDTA buffer prior to treatment with
RNase A (50 g/ml), 0.5% SDS, and proteinase K (500 g/ml). Cross-linking was
reversed by heating to 65°C for 6 h, and DNA was recovered by phenol-chloro-
form extraction and purified by precipitation with 2 M ammonium acetate-
ethanol. DNA was resuspended in 30 l of water, and 10 l was used for PCR
amplification with IFNA4, IFNA13, and IFNB promoter-specific primers for 30
cycles.
Affinity purification of polyhistidine-tagged IRF-5. Cells (5  107) were co-
transfected with IRF-5 and a combination of expression plasmids for 24 h. Cells
were then harvested and lysed under denaturating conditions using guanidium
lysis buffer (pH 7.8). Lysates were then passed through an 18-gauge needle and
centrifuged to remove cellular debris. Ni-charged ProBond resin beads (cata-
logue no. K850-01; Invitrogen) were preblocked by incubation with bovine serum
albumin and washed with binding buffer before incubation with cell lysates for
1 h. Beads were collected by centrifugation at 800  g for 1 h and washed with
native purification buffers with enhanced stringency (250 mM NaH2PO4, pH 8.0,
2.5 M NaCl, 3 M imidazole, protease and phosphatase inhibitor cocktails). Beads
were then washed with phosphate-buffered saline, resuspended in 1 loading
buffer, and heated to 95°C for 5 min, and bound proteins resolved by SDS-
polyacrylamide gel electrophoresis (PAGE). IRF-5 and associated proteins were
detected by immunoblotting with specific antibodies.
Transfections, immunoprecipitation, and immunoblot analysis. For the tran-
sient transfection assays, 2  106 cells were transfected with various expression
plasmids by using Polyfect transfection reagent (Qiagen). Empty vector DNA
was used to keep the total amount of transfected DNA constant (total, 4 g).
Samples were lysed in a radioimmunoprecipitation assay lysis buffer (20 mM Tris
[pH 7.9], 50 mM NaCl, 5 mM EDTA, 0.1% Nonidet P-40, 10% glycerol, 1 mM
DTT, 1 mM phenylmethylsulfonyl fluoride, and 0.2 mM protease inhibitor mix-
ture; Sigma). For SDS-PAGE, 10 to 20 g of total protein was resolved on 8 or
10% polyacrylamide gels and transferred to nitrocellulose or polyvinylidene
difluoride membranes. Membranes were blocked for 1 h at room temperature
with 5% dry skim milk powder in Tris-buffered saline–Tween 20 before overnight
incubation with the respective antibodies. The membranes were subsequently
incubated for 1 h at room temperature with horseradish peroxidase-conjugated
anti-mouse or anti-rabbit immunoglobulin G antibody (Amersham Biosciences),
and immunodetection was visualized by ECL reagents (Amersham), followed by
autoradiography on HyBlot CL film (Denville Scientific). Membranes were
stripped of bound antibodies using a stripping solution (Pierce). For Flag im-
munoprecipitation, anti-Flag affinity gel (Sigma A2220) was used according to
the vendor’s directions.
Luciferase reporter assay. 293T cells and IRAK1/ and TRAF6/ MEF
cells seeded on 24-well plates (1  105) were transfected with 100 ng of the
luciferase reporter plasmid together with a total of 400 ng of various expression
plasmids using Lipofectamine 2000 (Invitrogen). The total amounts of trans-
fected DNA were kept constant in all experiments by adjustment with empty
vector. Luciferase activity was measured 24 h later using a dual luciferase re-
porter assay system (Promega). The Renilla luciferase gene (20 ng) was cotrans-
fected and was used as an internal control plasmid. Each experiment was re-
peated four times. Data are expressed as means  standard deviations of four
replicates.
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RESULTS
IRF-5 undergoes K63-linked polyubiquitination in response
to TLR/MyD88-dependent signaling. The observation that
IRF-5 associates with TRAF-6 in the TLR-MyD88 signaling
pathway (28) prompted us to investigate whether the associa-
tion of TRAF6 with IRF-5 results in the ubiquitination of
IRF-5. To this effect, cells were transfected with murine IRF-5
(referred to here as IRF-5) and various combinations of
MyD88, TRAF6, and HA-tagged ubiquitin expression plas-
mids. At 24 h after transfection cells were lysed, and His-
tagged IRF-5 was purified by affinity purification on a Ni col-
umn. The results clearly show that MyD88-activated IRF-5
underwent a robust ubiquitination in cells expressing ectopic
ubiquitin and TRAF6 (Fig. 1A, lanes 4 and 6). The activation
of IRF-5 by MyD88 was necessary for this ubiquitination since
in the absence of MyD88 the ubiquitination of IRF-5 was
significantly weaker. When cells were expressing IRF-5 alone
or IRF-5 cotransfected with ubiquitin plasmid alone, IRF-5
was not ubiquitinated (Fig. 1A, lanes 2 and 3). These data show
that IRF-5 undergoes ubiquitination when activated by
MyD88. We also examined the ubiquitination of human iso-
forms of IRF-5, notably IRF-5 v4 and IRF-5 v5. Results show
that the Ni-purified HuIRF-5 variants undergo MyD88-
TRAF6-dependent ubiquitination (Fig. 1B, lanes 3 and 5). The
expression of IRF-5 variants, MyD88, and TRAF6 was de-
tected after immunoblotting from the input whole-cell lysate
(Fig. 1B). IRF-5 ubiquitination could also be detected in cell
lysates of 293T cells by immunoblotting when the cells were
transfected with IRF-5 in the presence of MyD88 but not in its
absence, showing that MyD88-mediated activation of IRF-5
enhances its ubiquitination.
TRAF6-mediated ubiquitination occurs predominantly
through K63-linked, rather than through K48-linked, chains. A
K63-linked modification does not target proteins for degrada-
tion but leads to activation of signaling functions. To deter-
mine whether ubiquitination of IRF-5 was K63 or K48 linked,
we used two ubiquitin mutant plasmids, in which residues 63 or
48 were mutated to arginine, i.e., K63R and K48R, respec-
tively. 293T cells were transfected with IRF-5 together with
MyD88, TRAF6, wild-type ubiquitin, and K63R and K48R
HA-tagged ubiquitin mutants (Fig. 1C). Cells were harvested
24 h posttransfection, and IRF-5 was purified on a Ni column,
analyzed by SDS-PAGE, and detected by immunoblotting with
IRF-5 (Fig. 1C, left panel) or ubiquitin-specific antibodies
(right panel). The results revealed that only the wild-type ubiq-
uitin and the K48R mutants mediated ubiquitination of IRF-5
(Fig. 1C, left panel, lane 6, and right panel, lane 8) while no
ubiquitination of IRF-5 was detected when the K63R mutant
was examined (left panel, lane 5, and right panel, lanes 6 and
7). These results show that ubiquitination of IRF-5 is K63
linked.
We also examined whether engagement of TLRs leads to the
ubiquitination of endogenous IRF-5. To this effect, we used
the RAW264.7 macrophage cell line, which expresses TLR7
and responds to the TLR7 ligand R848 to activate both IRF-7
and IRF-5 (17, 25). Cells were mock treated (with dimethyl
sulfoxide [DMSO]) or stimulated with R848 for 8 h or left
untreated. The polyubiquitinated proteins were enriched on an
antiubiquitin column and then subjected to immunoblotting
with anti-IRF-5 antibody. As a positive control, RAW264.7
cells were also cotransfected with IRF-5, MyD88, TRAF6, and
ubiquitin expression plasmids. A significant enrichment of
ubiquitinated IRF-5 was detected in R848-treated cells and in
cells transfected with MyD88, TRAF6, and ubiquitin (Fig. 1D).
The ubiquitination pattern of the endogenous IRF-5 was sim-
ilar to that obtained in the cotransfection experiment. No ubiq-
uitinated endogenous IRF-5 was detected in the untreated or
DMSO-treated cells. The Western blot analysis of cell lysates
of R848-treated and transfected cells also revealed ubiquiti-
nated IRF-5. Interestingly, the levels of expression of IRF-5 in
untreated or mock-treated cells were very low, and IRF-5 was
detected in total cell lysates only in R848-treated or trans-
fected cells but not in the controls, indicating that TLR signal-
ing upregulated IRF-5, probably via autocrine IFN signaling.
However, when enriched by immunoprecipitation, IRF-5 was
detected in lysates of untreated cells, but it was not ubiquiti-
nated (Fig. 1D, lower panel).
FIG. 1. IRF-5 undergoes K63-linked polyubiquitination in a MyD88-dependent pathway. (A) 293T cells transfected with a total (4 g) of
His-tagged IRF-5 (lanes 2 to 6), MyD88 (lanes 4, 6, and 7), and TRAF6 (lanes 5, 6, and 7) together with HA-ubiquitin (lanes 3 to 7) IRF-5 were
affinity purified from cell lysates, using Probond Ni2-charged resin. Bound proteins were separated on an SDS gel, and IRF-5 was identified by
immunoblotting (IB) with anti-IRF-5 (upper panel) and antiubiquitin antibody (lower panel) after stripping the same blot. Whole-cell lysate was
also immunoblotted with tubulin, anti-MyD88, anti-TRAF6, and anti-HA antibodies. (B) 293T cells were transfected with IRF-5v4 or IRF-5v5 and
ubiquitin together with MyD88 and TRAF6. At 24 h after transfection cells were lysed, and IRF-5v4 was immunoprecipitated with Flag antibodies.
IRF-5v5 was affinity purified on Ni resin. Proteins were separated on an SDS gel and immunoblotted with anti-IRF-5 and antiubiquitin antibody
(upper panels). The relative levels of IRF-5, -actin, and TRAF6 in the whole-cell lysate determined by immunoblotting are shown. (C) 293T cells
were transfected with His-tagged IRF-5 (lanes 2 to 6 in the left panel and lanes 2 to 8 in the right panel), MyD88 (lanes 4 to 6 in the left panel
and lanes 4 to 6 in the right panel), TRAF6 (lanes 4 to 6 in the left panel and lanes 3, 8, and 9 in the right panel) together with HA-ubiquitin (lanes
3 and 4 in the left panel and lanes 3 and 4 in the right panel) or a K63R HA-ubiquitin mutant (lane 5 in the left panel and lanes 6 and 7 in the
right panel) or K48R ubiquitin mutant (lane 6 in the left panel and lanes 7 to 8 in the right panel). His-tagged IRF-5 was affinity purified on Ni
resin and blotted with anti-IRF-5 (left panel) or antiubiquitin (right panel) serum. The expression of IRF-5, MyD88, TRAF6, and K48 or K63
HA-ubiquitin detected in the input cell lysates was detected by immune blotting (lower panels). (D) Ubiquitination of the endogenous IRF-5.
RAW264.7 cells were either treated with DMSO or stimulated with a 100 nM concentration of TLR7 agonist R848 for 8 h to engage TLR7-MyD88
pathway that leads to IRF-5 activation. As a positive control, cells were transfected with IRF-5 together with MyD88, TRAF6, and ubiquitin. Cells
were lysed with radioimmunoprecipitation assay buffer, and ubiquitinated IRF-5 was immunopurified using antiubiquitin beads. The specifically
bound proteins were subjected to SDS-PAGE and immunoblotted with IRF-5 antibodies (upper panel). The total cell lysate was probed with IRF-5
(lower panel). The cell lysate from unstimulated RAW264.7 cells was immunoprecipitated with IRF-5 and immunoblotted with IRF-5 to
demonstrate the expression of an endogenous IRF-5 (lower panel). Immune blotting with ubiquitin antibodies did not detect any IRF-5 (data not
shown). Ub, ubiquitin; IgG, immunoglobulin G.
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TRAF6 consensus binding motif in IRF-5 is essential for
IRF-5 polyubiquitination. TRAF6 is a member of the TRAF
family that has been shown to function as an E3 ubiquitin
ligase (27). Binding of TRAF6 to IRF-7 or IRF-5 has been
demonstrated previously (18, 28). To determine whether the
ubiquitination of IRF-5 is mediated by TRAF6 or whether
other members of the TRAF family also contribute to IRF-5
ubiquitination in the TLR signaling pathway, we have exam-
ined the ubiquitination of IRF-5 in TRAF6/ MEFs. These
cells were cotransfected with IRF-5 and ubiquitin in combina-
tion with either MyD88 or TRAF6, and at 24 h posttransfec-
tion, IRF-5 was analyzed by immunoblotting. The results
showed that MyD88 activation of IRF-5 ubiquitination was
compromised in MEFs lacking TRAF6, which was restored
upon reconstitution with ectopic TRAF6. (Fig. 2A, lane 4),
thus indicating that TRAF6 contributes to K63-linked ubiq-
uitination of IRF-5. A very slow mobility band was observed in
HA immunoblots of cellular extracts when IRF-5 and MyD88
were cotransfected into TRAF6-negative cells, indicating the
possible involvement of another member of the TRAF family
or another cellular E3 ubiquitin ligase in TRAF6-independent
IRF-5 polyubiquitination.
We also analyzed ubiquitination of a set of HuIRF-5v4 C-
terminal deletion mutants which were tagged with a Flag
epitope. A schematic representation of these deletion mutants
is shown in Fig. 2B. The mutants were transfected together
with ubiquitin, MyD88, and TRAF6 expression plasmids into
293T cells. Western blot analysis of transfected lysates showed
that all the mutants were expressed at comparable levels.
IRF-5 was next immunoprecipitated and immunoblotted with
anti-IRF-5 antibodies. As shown in Fig. 2B, full-length IRF-5
shows several slowly moving bands. These bands were also
detected by ubiquitin antibodies, indicating that they represent
polyubiquitinated IRF-5 (data not shown). In contrast, none of
the deletion mutants was ubiquitinated (Fig. 2B, lanes 3 to 5),
and only full-length IRF-5 was ubiquitinated (lane 2). These
data indicate that the ubiquitination sites targeted by the
TRAF6 pathway are localized in the C	-terminal region of the
IRF-5 polypeptide. Sequence analysis of this region identified
a putative TRAF6 consensus binding motif [PXEXX(Ar/Ac),
where Ar/Ac is an aromatic/acidic residue] (32) near the C	-
terminal region of IRF-5 (Fig. 2C). IRF-5 mutants which have
the carboxyl-terminal region with a deletion of the TRAF6
recognition site are not ubiquitinated (Fig. 2B). Interestingly,
this region also contains two lysine residues. To examine the
role of these two lysine residues in IRF-5 ubiquitination, we
mutated both lysine K410 and K411 to arginine and tested the
ubiquitination of this mutant (K410/K411R). 293T cells were
cotransfected with IRF-5 or the IRF-5 K410/K411R mutant
together with MyD88, TRAF6, and ubiquitin plasmids. After
the Ni affinity purification of IRF-5, samples were immuno-
blotted with anti-IRF-5 or with anti-ubiquitin antibodies (Fig.
2C). Results shown in Fig. 2C revealed that while IRF-5 un-
derwent a robust ubiquitination in a MyD88-TRAF6-depen-
dent manner, no ubiquitination of the double point mutant
K410/K411R was observed (lanes 4). We also examined
whether the spliced murine IRF-5 bone marrow variant (IRF-
5-BMv) is ubiquitinated; however, no ubiquitination of this
mutant was detected (lane 3). The immunoblotting of the
transfected lysates showed that all the IRF-5s encoded by the
respective plasmids were expressed at equivalent levels. These
data indicate that deletion of the TRAF6 recognition site in
the IRF-5 peptide or mutation of the lysines 410 and 411
prevents TRAF6–IRF-5 interactions or that the lysines 410
FIG. 2. IRF-5 is polyubiquitinated by the E3 ligase TRAF6. (A) TRAF6/ MEFs were cotransfected with IRF-5, MyD88, and HA-ubiquitin
in the presence and absence of TRAF6. At 24 h posttransfection, cell lysates were immunoblotted with anti-IRF-5 (upper panel) or anti-HA
epitope antibodies (middle panel). To verify TRAF6 expression, the blot was reprobed with anti-TRAF6 antibody (lower panel). Levels of -actin
show equal loading of protein. (B) Schematic structure of C-terminal deletions of IRF-5v4. DBD, DNA binding domain; IAD, interacting domain.
Amino acid regions that are deleted in the IRF-5 mutants are indicated. Flag-tagged full-length IRF-5 or its deletion mutants were transfected to
293T cells together with MyD88, TRAF6, and ubiquitin. At 24 h posttransfection cells were lysed, and lysates were subjected to immunoprecipi-
tation using anti-Flag-coupled beads followed by immunoblotting with anti IRF-5 antibody. IRF-5 and its deletion mutants were detected in cell
lysates by immunoblotting with anti-Flag antibody. (C) A schematic illustration of point mutations at TRAF6 consensus recognition motif and a
deletion in IRF-5-BMv. 293T cells were transfected with murine IRF-5 (positive control), IRF-5-BMv, and IRF-5 K410/K411R together with
MyD88, TRAF6, and ubiquitin. His-purified IRF-5 was detected by immunoblotting with anti-IRF-5 (upper panel). IRF-5-BMv and IRF-5 mutant
expression in cell lysates were detected by immunoblotting, and the relative levels of -actin indicate equal protein loading. (D) Binding of TRAF6
to IRF-5 and its mutants. Cells were cotransfected with Flag-IRF-5 or its deletion mutants together with MyD88 and HA-ubiquitin expression
plasmids (left). Twenty-four hours later the cells were lysed, and the lysates were precipitated with Flag antibodies; the presence of IRF-5 and
TRAF6 in the precipitates was detected by Western blotting with IRF-5 or TRAF6 antibodies. The relative levels of transfected IRF-5, its mutants,
and TRAF6 in the input lysates were detected by Western blotting. The IRF-5-positive band in the control sample (lane 1) was caused by a leaking
well. Lysates from cells cotransfected with IRF-5, the IRF-5 K410/K411R mutant, and IRF-5-BMv with MyD888 and TRAF6 were immunopre-
cipitated with TRAF6 antibodies, and the levels of IRF-5 and TRAF6 in immunoprecipitated samples were detected by immunoblotting with
IRF-5 or TRAF6 antibodies (right panels). The relative levels of transfected IRF-5, the IRF-5 K410/K411R mutant, IRF-5-BMv, and TRAF6 in
the input lysates were detected by immunoblotting with respective antibodies. (E) The two C-terminal deletion mutants of IRF-5v5 containing the
TRAF6 consensus recognition sequence PREKKL are shown schematically. The lysates of cells cotransfected with full-length IRF-5v5 or its
mutants and MyD88 and TRAF6 were immunoprecipitated with Flag antibody, and IRF-5 was detected by immunoblotting with IRF-5 antibody
(upper panel). The same blot was stripped of bound antibody and blotted with TRAF6 antibody (middle panel). The levels of expression of IRF-5
and TRAF6 in input lysates are shown in the lower panel. (F) Mutation in the TRAF6 consensus recognition motif of IRF-5 blocked activation
of IFNA4 reporter. 293T cells were cotransfected with an IFNA4-luc reporter plasmid (10 ng) together with the indicated combination of MyD88
(10 ng), TRAF6 (10 ng), and ubiquitin (5 ng) and 10 ng each of IRF-5, IRF-5v5, IRF-5v4, and the IRF-5 K410/K411R mutant. Luciferase activity
was measured 24 h after the transfections. Cells were also transfected with IRF-5, MyD88, and TRAF6 and together with TLR7 expression
plasmid. Sixteen hours after transfections stimulated with 10 nM R848 for 8 h, luciferase activity was measured in cell lysates (right panel).
(G) IFNA4-luciferase (Luc) reporter and IRF-5 plasmids were cotransfected into TRAF6/ MEFs and wild-type MEFs together with MyD88,
TRAF6, and ubiquitin as indicated. The levels of DNA were kept constant in all transfection experiments, and the data are expressed as means 
standard deviations of four replicates. Ub, ubiquitin; IP, immunoprecipitation; IB, immunoblotting; nt, nucleotides.
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and 411 are the target sites of TRAF6-mediated ubiquitina-
tion.
To distinguish between these two possibilities, we examined
the interaction of TRAF6 with the deletion mutants of IRF-5
as well as with the K410/K411R mutant. To this effect, cell
lysates from cells transfected with MyD88, TRAF-6, IRF-5 or
its mutants were immunoprecipitated with TRAF6 antibodies,
and the presence of IRF-5 in precipitates was detected by
immunoblotting with IRF-5 antibodies (Fig. 2D). Only the
full-length IRF-5 but not any of the mutants tested interacted
with TRAF6, indicating that TRAF6 interacts exclusively with
the carboxyl-terminal part of the IRF-5 peptide (Fig. 2D, left
panel). The data further show that the K410/K411 mutation
did not affect binding of TRAF6 to IRF-5; these data indicate
therefore, that K410 and K411 are direct targets of TRAF6-
mediated ubiquitination. We have previously shown that the
transcriptional activity of the MyD88-activated IRF-5-BMv
was significantly impaired (23). This mutant has an internal
deletion of 288 nucleotides representing part of exon 4, exon 5,
and part of exon 6 (Fig. 2C). We have therefore tested whether
IRF-5-BMv is ubiquitinated and found that this variant was
compromised in its ability to be targeted for ubiquitination
(Fig. 2C, lane 3) and is also compromised in its ability to
interact with TRAF6 (Fig. 2D, right panel, lane 3). These data
indicate that in IRF-5-BMv, the PREKKL site is not accessible
for TRAF6 recognition.
To determine whether the PREKKL recognition site alone
is sufficient for TRAF6 binding to IRF-5, we constructed two
IRF-5 mutants which had the C	 terminus deleted just after the
PREKKL domain or after the PREKKL domain and four
additional amino acids (Fig. 2E). We found that both of these
mutants were compromised in their ability to bind IRF-5 and
consequently to be ubiquitinated (lanes 2 and 3). These data
indicate that although the K410 and K411 in the PREKKL
domain are the TRAF6 ubiquitination targets of IRF-5, the
binding of TRAF6 to IRF-5 requires not only the PREKKL
site but also the C-terminal region of IRF-5.
To determine whether the ubiquitination of IRF-5 contrib-
utes to its transcriptional activation, we used transient trans-
activation assays. Cells were transfected with an IFNA4 re-
porter plasmid together with IRF-5, IRF-5v5, IRF-5v4, or the
IRF-5 K410/K411R mutant in the presence and absence of
MyD88, TRAF6, and ubiquitin expression plasmids (Fig. 2F).
The results showed that neither MyD88, TRAF6, nor ubiquitin
alone activated the IFNA4 gene promoter (Fig. 2F, left panel,
lanes 1 to 3). Also the activation by IRF-5, IRF-5v5, IRF-5v4,
or the IRF-5 K410/K411R mutant alone was insignificant
(lanes 5 to 8). However, in the cells expressing MyD88,
TRAF6, and ubiquitin, both IRF-5 and IRF-5v5 enhanced the
activity of IFNA4 promoter by about five- to sixfold (compare
lane 4 and lanes 9 and 10), while the enhancement by IRF-5v4
was only about threefold (lane 11). In contrast, under the same
conditions, the IRF-5 K410/K411R mutant failed to stimulate
the IFNA4 promoter above the base level (lane 12), suggesting
that the K410 and K411 are the primary lysine residues tar-
geted by TRAF6 and that the ubiquitination of IRF-5 en-
hances its transcriptional activity. IRF-5 is activated by the
TLR7 pathway (25). We therefore examined whether the ac-
tivation of ectopic TLR7 by its ligand R848 would enhance the
stimulation of the IFNA4 promoter by IRF-5; however, the
TLR7-activated pathway did not further enhance the MyD88
activation of IRF-5 (Fig. 2F, right).
The critical role of MyD88-TRAF6-mediated ubiquitination
of IRF-5 in the activation of type I IFN and proinflammatory
cytokine gene transcription was also evaluated by performing
reporter assays in TRAF6/ MEFs (Fig. 2G). Reporter plas-
mids containing the IFNA4 promoter were cotransfected with
IRF-5 and a combination of ubiquitin and TRAF6 plasmids
into TRAF6/ or wild-type MEFs (Fig. 2G). The data con-
firm that in the absence of TRAF6, IRF-5 expressed with
ubiquitin or together with MyD88 was unable to substantially
activate IFNA4 reporter plasmid in TRAF6/ cells (Fig. 2G,
lanes 2 and 3). However, coexpression of TRAF6 activated the
reporter activity to the levels seen in wild-type MEFs (Fig. 2G,
lanes 4 and 5). No activation of the IFNA4 promoter was seen
in IRF-5 untransfected control cells (lanes 6 and 7). These
results strongly suggested that TRAF6-mediated IRF-5 ubiq-
uitination enhances IRF-5-mediated activation of type I IFN
genes.
Association of IRF-5 with IRAK1. IRAK1 associates with
MyD88 and IRF-7 and is thought to be a part of the MyD88,
TRAF6, and IRF-7 complex. IRF-5 was previously shown to
interact with both MyD88 and TRAF6 (28). Whether IRAK1
also associates with the IRF-5 complex is unknown. To deter-
mine whether IRF-5 associates with IRAK1, IRF-5 and
IRAK1 were transfected into HEK-1A1 cells, a 293T cell line
that lacks functional IRAK1 (19), with the combination of
MyD88-, TRAF6-, and ubiquitin-expressing plasmids as shown
in Fig. 3A. IRAK1 was immunoprecipitated from the trans-
fected cells, and the coprecipitated IRF-5 was detected by
immunoblotting. Interaction of IRAK1 and IRF-5 was de-
tected in cells coexpressing IRF-5 and IRAK1 either alone or
in the presence of TRAF6 and ubiquitin (Fig. 3A, lanes 2 and
5). However, no association between IRF-5 and IRAK1 was
detected in cells expressing MyD88, indicating that MyD88
expression may disrupt the IRF-5 and IRAK1 association. This
may be attributed to a competition between IRF-5 and over-
expressed ectopic IRAK1 for binding to MyD88. Also HEK-
1A1 cells, which lack functional IRAK1 (19), may contain
additional alterations in the TLR pathway that affect formation
of IRF-5, MyD88, and IRAK1 complex. Western blotting of
ectopic IRAK1 indicates that IRAK1 is posttranslationally
modified in the cells expressing MyD88, TRAF6, and ubiq-
uitin. Additional studies will have to determine the nature of
this modification.
We next examined whether the ubiquitination of IRF-5 was
dependent on IRAK1. To this effect HEK-1A1 cells were
transfected with IRF-5 and ubiquitin in combination with
MyD88 and TRAF6 with or without IRAK1, as shown in Fig.
3B. We have previously shown that IRAK1 is required for the
activation of IRF-5 in response to TLR7 signaling (25). His-
tagged IRF-5 was affinity purified and analyzed for its ubiq-
uitination status by SDS-PAGE. Consistent with our previous
results, these results showed that IRF-5 ubiquitination is crit-
ically dependent on IRAK1. In the absence of IRAK1,
MyD88-activated IRF-5 was not ubiquitinated by TRAF6 (Fig.
3B). However, when cells were reconstituted with ectopic
IRAK1 together with TRAF6, robust ubiquitination of IRF-5
was detected (Fig. 3B, lane 7). A kinase-inactive mutant of
IRAK1, (IRAK1 D340N) was unable to rescue the ubiquitina-
7302 BALKHI ET AL. MOL. CELL. BIOL.
ββ
FIG. 3. IRF-5 associates with IRAK1. (A) IRAK1/ 293TI1A cells were transfected with IRAK1, His-tagged IRF-5, MyD88, TRAF6, and
ubiquitin (Ub). Cell lysates were immunoprecipitated (IP) with anti-IRAK1 antibody and immunoblotted with either anti-His antibody or IRAK1
as indicated. The expression of transfected plasmids in cell lysates was detected by immunoblotting with respective antibodies (lower panel).
(B) 293TI1A cells, transfected with His-tagged IRF-5 (lanes 2 to 8), MyD88 (lanes 3, 5, 6, 8, and 9), TRAF6 (lanes 4, 7, and 8), or IRAK1 (lanes
6 to 9) together with HA-ubiquitin (lanes 3 to 8). IRF-5 was His purified and analyzed on an SDS gel by immunoblotting (IB) with anti-IRF-5
antibody (upper panel) and subsequently with anti-HA antibodies (middle panel). The relative levels of MyD88 IRAK1 and -actin in input cell
lysates were detected by immunoblotting with the respective antibodies.
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tion of IRF-5 in IRAK1-deficient cells (data not shown). Co-
expression of IRF-5 with either MyD88-IRAK1 or MyD88-
IRAK1-TRAF6 failed to restore IRF-5 ubiquitination (Fig.
3B, lanes 6, 8, and 9). These results are in agreement with our
observations (Fig. 3A) that MyD88 may disrupt IRAK1 and
IRF-5 association.
The kinase activity of IRAK1 was required for the ubiquiti-
nation of IRF-5 since the kinase-inactive mutant of IRAK1 was
unable to rescue IRF-5 ubiquitination in IRAK null cells (data
not shown). The requirement of IRAK1 for the IRF-5 ubiq-
uitination could indicate that phosphorylation of IRF-5 may be
a prerequisite for efficient ubiquitination. It was shown re-
cently that IRAK1 phosphorylates IRF-7 in vitro, suggesting
that IRAK1 may serve as an IRF-7 kinase; however, direct
phosphorylation of IRF-7 by IRAK1 in vivo was not demon-
strated. Whether IRF-5 is directly phosphorylated by IRAK1
or another IRAK1-activated kinase is not known, and experi-
ments are under way to address this issue.
IRF-5 ubiquitination promotes nuclear localization, recruit-
ment to the virus-responsive element (VRE) of type I IFN
promoters, and stability. It was shown that IRAK1 deficiency
impaired nuclear localization of IRF-7 in the MyD88 sig-
naling pathway (29). Since our data show that ubiquitination
of IRF-5 is dependent on IRAK1, we examined whether
IRF-5 translocates to the nucleus in HEK-1A1 cells upon
activation by MyD88. HEK-1A1 cells were cotransfected
with IRF-5 and ubiquitin and combinations of MyD88- and
TRAF6-expressing plasmids. Cytoplasmic and nuclear ex-
tracts were prepared at 24 h posttransfection, and the rela-
tive levels of IRF-5 were detected by immunoblotting. The
data show that MyD88-activated IRF-5 was not translocated
to the nucleus in HEK-1A1 cells unless the cells were re-
constituted with ectopic IRAK1. The data also revealed that
IRF-5 was able to translocate into the nucleus of IRAK1
null cells upon overexpression of TRAF6 (Fig. 4A) since
TRAF6 works downstream of IRAK1.
To demonstrate directly that the ubiquitination of IRF-5 is
necessary for or facilitates nuclear localization of IRF-5, we
have followed the accumulation of IRF-5 ubiquitin-deficient
mutants in the nucleus (Fig. 4B). 293T cells were transfected
either with full-length IRF-5, IRF-5 ubiquitin deficient point
mutants (K410/K411R), or a C-terminal deletion mutant (IRF-
5
480, IRF-5 with a deletion of residues 480 to 539) together
with a combination of MyD88, TRAF6, and ubiquitin as shown
in Fig. 4B. Cells were lysed, and nuclear and cytoplasmic frac-
tions were prepared at 12 h and 24 h posttransfections. As we
have shown previously (6), low levels of ectopic IRF-5 were
present in the nucleus even in unstimulated cells; however, the
relative levels of nuclear IRF-5 were significantly increased in
cells expressing MyD88 and TRAF6 (Fig. 4B, nuclear frac-
tion). In contrast, in cells expressing MyD88 and TRAF6, the
ubiquitin-deficient mutants IRF-5 K410/K411R and IRF-5

480 accumulated in the cytoplasm (Fig.4B, lanes 8 and 9), and
their relative levels in the nucleus correspond to those in un-
stimulated cells (compare lanes 8 and 9 and lanes 2 and 3). The
relative levels of -tubulin and Sp-1 were monitored as loading
controls for the cytoplasmic and nuclear proteins, respectively.
While the levels of tubulin were comparable in all the samples,
the relative levels of Sp-1 were significantly higher in cells
expressing MyD88 and TRAF6, suggesting that the MyD88
signaling pathway stimulates Sp-1 expression. Altogether these
results demonstrate the importance of IRF-5 ubiquitination in
its translocation to the nucleus.
We also examined the recruitment of IRF-5 to the VRE
region of IFNA promoters and to the positive regulatory do-
main III/I region of the IFNB promoter (Fig. 4C) upon its
activation by the MyD88-TRAF6-ubiquitin pathway. A ChIP
assay was performed using a previously tested IRF-5-specific
antibody. IRF-5 binding to the IFNA4, IFNA13, and IFNB
promoters dramatically increased upon IRF-5 activation by
MyD88 and by overexpression of TRAF6 and ubiquitin (Fig.
4C, lane 3, 4, and 5). No IRF-5 binding to the IFNA VRE was
seen in controls, and only trace amounts of IRF-5 bound to the
IFNB positive regulatory domain elements (Fig. 4C, lane 1, 2,
and 6). These data indicate that the MyD88-mediated pathway
stimulates binding of IRF-5 to the type I IFN promoters and
that overexpression of TRAF6 and ubiquitin is sufficient to
mimic MyD88 activation of IRF-5 and IRF-5 DNA binding
activity.
It was shown that K63-linked ubiquitination increased the
stability of p53 (8). We therefore wanted to determine if the
K63-ubiquitinated IRF-5 was also more stable. 293T cells
were transfected with IRF-5 alone or in combination with
MyD88, TRAF6, and ubiquitin. Twelve hours after the
transfection cells, were treated with cycloheximide (CHX)
to stop de novo protein synthesis, and the relative levels of
FIG. 4. Ubiquitination of IRF-5 promotes nuclear transport, binding to type I IFN promoters and IRF-5 stabilization. (A). IRF-5 nuclear
localization of IRF-5 in IRAK1/ cells. 293TI1A cells were cotransfected with IRF-5, MyD88, TRAF6, and ubiquitin (Ub). Nuclear and
cytoplasmic fractions were prepared 24 h after the transfections, and proteins were separated on SDS gels and immunoblotted (IB) with IRF-5
antibodies. To demonstrate equal loading, blots were stripped and immunoblotted with -actin (cytoplasmic fraction), and the purity of the nuclear
fraction was demonstrated by blotting with anti-RelA antibody. Immune blotting with anti-IRAK1 antibody was used to determine the levels of
ectopic IRAK1. (B) 293T cells were transfected with IRF-5, the IRF-5 K410/K411R mutant, and the IRF-5
 (with a deletion of residues 480 to
539) mutant, and cytoplasmic and nuclear proteins were resolved by SDS-PAGE and analyzed by Western blotting with anti-IRF-5, anti-Sp1
(nuclear fraction), and anti--tubulin (cytoplasmic fraction) antibody. (C) The association of IRF-5 with the promoters of the endogenous IFNA
and IFNB genes was determine by ChIP assay in 293T cells transfected with IRF-5, MyD88, TRAF6, and ubiquitin as described in Materials and
Methods. The sequences of the PCR-amplified promoter fragments containing the IRF-E binding site are shown. (D) Ubiquitination leads to
stabilization of IRF-5. The left panel shows relative levels of IRF-5 in cells transiently expressing IRF-5, and the right panel shows IRF-5 levels
in cells in which IRF-5 was coexpressed with MyD88, TRAF6, and ubiquitin. Ethanol control is a control sample cultured in the absence of CHX.
Gels were scanned, and the ratios of IRF-5 to -actin are shown as a function of time. (E) The relative levels of ubiquitinated proteins in cell lysates
from 293T cells expressing IRF-5, MyD88, TRAF6, and ubiquitin and cultured with either DMSO (left panel) or 10 M MG132 (right panel) for
6 h. The blots were reprobed with anti-IRF-5 (middle panel) and -tubulin (lower panel) antibodies. (F). Proposed model of molecular mechanism
leading to IRF-5 activation by a TLR7/9-activated, MyD88-dependent pathway.
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IRF-5 were monitored for 2 h (Fig. 4D). The results showed
that while the ectopic IRF-5 protein starts to be degraded as
early as 60 min after CHX treatment, when IRF-5 was
coexpressed with MyD88, TRAF6, and ubiquitin, there was
no significant degradation of IRF-5 until 120 min posttreat-
ment (right panel). The relative levels of -actin at different
time points of CHX treatment are shown as a control for
equal protein loading. These data show that the MyD88-
activated ubiquitinated IRF-5 is more stable. Whether the
association of ubiquitinated IRF-5 with the other members
of the MyD88-activated ternary complex also contributes to
its stability is not known and cannot be excluded. Treatment
with the proteasome inhibitor MG132 (Fig. 4E) did not
increase significantly the levels of IRF-5 ubiquitination,
compared to the untreated controls, confirming that K63-
linked IRF-5 ubiquitination was not targeted for degrada-
tion by the proteasome.
DISCUSSION
We have shown in this study that IRF-5 is targeted for
K63-linked polyubiquitination in an IRAK1- and TRAF6-de-
pendent manner and that lysines 410 and 411 in the carboxyl-
terminal region of IRF-5 polypeptide are the target residues
for TRAF6-mediated ubiquitination. We show that TRAF6 is
required for IRF-5 ubiquitination and that this activity de-
pends on the presence of kinase-competent IRAK1. Ubiquiti-
nation of IRF-5 facilitates its transport to the nucleus and
binding and activation of the promoters of the IFNA and IFNB
genes (Fig. 4F). Mutations of lysines 410 and K411 to arginine
localized in a putative TRAF6 consensus binding site, PXEX
X(Ar/Ac), prevented ubiquitination and nuclear localization of
IRF-5 K410/K411R in response to MyD88 activation while
these changes did not affect binding of TRAF6. These findings
suggest that the K63-linked ubiquitination of IRF-5 is a critical
requirement that regulates the activity of IRF-5 in the MyD88-
activated antiviral pathway. However, the ubiquitination of
IRF-5 occurs at low levels, and even small degrees of IRF-5
ubiquitination can enhance IRF-5 signaling. We also show that
the spliced variant IRF-5-BMv that contains a large internal
deletion of 288 nucleotides in the region representing exon 5
and parts of exons 4 and 6 is not ubiquitinated by the MyD88-
activated signaling pathway. TRAF6 also failed to bind the
IRF-5-BMv variant, thus indicating that the internal deletion
in the IRF-5 polypeptide affects its secondary structure and
masks the TRAF6 recognition site. We have shown previously
that the transcriptional activity of IRF-5-BMv is significantly
impaired (23). In contrast, the MyD88-activated HuIRF-5v4
that contains only 48 nucleotide deletions in exon 6 is still
effectively ubiquitinated and is transcriptionally active. Similar
to IRF-5, IRF-7 also interacts with TRAF6 and is K63 poly-
ubiquitinated (18) by the MyD88 signaling pathway. However,
the analysis of IRF-7 ubiquitination has shown that the region
between amino acids 238 and 285 of IRF-7 is important for
both TRAF6 binding and polyubiquitination of IRF-7 (18).
Thus, it is not clear whether the impairment of IRF-7 ubiq-
uitination reflects the inability of TRAF6 to bind IRF-7. Also,
the functional consequences of IRF-7 ubiquitination have not
yet been established.
Our study provides key new insights into the molecular
mechanisms of IRF-5 activation. We along with others have
shown previously that IRF-5 is activated by TLR7 and TLR9
signaling, which relies on the adapter molecule MyD88 (28),
but not by the TLR3 or TLR4 MyD88-independent pathway
(25). TLR7 and TLR9 use only MyD88 as an adapter and
activate both IRF-7 and IRF-5. MyD88 is also activated by
TLR2 and TLR4, but these TLRs induce either very little
IFN- (TLR4) or none at all (TLR2) although they effectively
activate NF-B. Whether the presence of any of the additional
adaptors associated with TLR2 or TLR4 (MyD88 and TIRAP
with TLR2 and MyD88, TIRAP, TRIF, and Mal with TLR4)
interferes with the formation of MyD88, IRAK1, TRAF6, and
IRF-5 signaling complex is not known.
TRAFs are major signal transducers of the tumor necrosis
factor receptor family. TRAF6 is a ubiquitin ligase-containing
RING domain that was shown to be a key factor for the NF-B
activation by interleukin-1receptor, TLR, and nucleotide
oligomerization domain 2 signaling pathways (2, 1). Major bio-
logical effects of TRAF signaling are mediated by activation of
NF-B and Ap-1 family members. The unique biological
functions of TRAF6 are determined by its C-terminal do-
main that does not interact with peptides recognized by
TRAF1, -2, -3, or -5. Thus, TRAF6 binds to distinct peptides
from those binding TRAF2 or TRAF3 (32). TRAF6 signal-
ing downstream from TLR7 or TLR9 involves association of
TRAF6 with IRAK4 and IRAK1. Full-length IRAK1 con-
tains three potential TRAF6 binding sites, suggesting that
these TRAF6 binding sites in IRAK1 contribute to TRAF6
activation. Peptides derived from this TRAF6-interacting
motif inhibited TRAF6-mediated signal transduction (32).
We have shown that IRAK1, but not an IRAK1 kinase-
inactive mutant, regulates TRAF6-mediated ubiquitination
of IRF-5, suggesting that the function of IRAK1 is required
for the activation of TRAF-6 and consequent TRAF6-
mediated ubiquitination of IRF-5.
It was shown that TRAF6 also binds to TRIF (24), where
it recruits TRIF-associated TBK-1 and IB kinase ε (IKKε).
However, the activation of IRF-5 by the TRIF-dependent
pathway has not been observed. It was shown that phosphor-
ylation of IRF-7 in the MyD88-mediated pathway does not
require TBK-1 and is instead dependent on IRAK1. How-
ever, direct phosphorylation of IRF-7 by IRAK1 was not
examined (18). IKK was also shown to be involved in the
TLR7 and TLR9 mediated induction of IFN-. It was shown
that IKK activates IFNA promoter in synergy with IRF-7,
while the induction of IFNB was not greatly modulated. It
remains to be clarified whether IKK cooperates with
IRAK-1 (16) in this pathway or in the activation of IRF-5.
Thus, the protein kinase that serves as an IRF-5 kinase in
the MyD88-dependent pathway and the role of phosphory-
lation have yet to be clearly elucidated. Further studies are
also required to determine whether the MyD88 and New-
castle disease virus activation of IRF-5 targets the same or
distinct serine residues.
Recently another member of the TRAF family, TRAF3,
has been implicated as a part of MyD88- and TRIF-depen-
dent signaling complexes (14). A comparison of the function
of TRAF3 and TRAF6 has shown that TRAF6 has a key
role in MyD88 signaling but not in TRIF signaling. TLR9-
induced activation of inflammatory genes was dependent on
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TRAF6, while the TLR3 activation was TRAF6 indepen-
dent. These authors concluded that MyD88 activation re-
cruits both TRAF3 and TRAF6, but the TRAF6-dependent
pathway results in the activation of NF-B and participates
in the induction of inflammatory cytokines while the TRAF3
pathway recruits TBK-1 and has an important role in the
TRIF-dependent activation of IFN genes. Our data clearly
identify IRF-5 as an additional effector of the TRAF6 path-
way. Thus, in the TLR7/9 and MyD88 pathways, TRAF6
leads to activation of the IKK, mitogen-activated protein
kinase, and IRF-5 pathways. However, one difference be-
tween the MyD88-mediated activation of IRF-5 and type I
IFN production and NF-B-mediated activation of inflam-
matory cytokines is the distinct requirement for IRAK1 in
the antiviral pathway. As we have shown in this study,
IRAK1 associates with IRF-5 and is required for MyD88-
dependent IRF-5 ubiquitination and activation. Similarly,
IRAK1 was required for activation of IRF-7 (29). However,
MyD88 activation of mitogen-activated protein kinase was
not impaired by IRAK1 deficiency (29), and the activity of
IRAK1 was not required for NF-B activation (19). These
findings imply that the specificity of TRAF6 recruitment to
the antiviral pathway may be determined by the formation of
the MyD88, IRAK1, and TRAF6 signaling complex and its
association with IRF-5 or IRF-7.
In summary, our study highlights the importance of IRF-5
ubiquitination in the MyD88-mediated antiviral signaling path-
way. Further understanding of the molecular mechanisms in-
volved in the IRF-5-induced inflammatory pathway will help to
elucidate the role that IRF-5 plays in the pathophysiology of
autoimmune diseases such as SLE.
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